On March 31, 2020, Fernandez Montes, A.; Vazquez Rivera, F.; Martinez Lago, N.; Covela Rua, M.; Cousillas Castineiras, A.; Gonzalez Villarroel, P.; de la Camara Gomez, J.; Mendez Mendez, J. C.; Salgado Fernandez, M.; Candamio Folgar, S.; Reboredo Lopez, M.; Carmona Campos, M.; Gallardo Martin, E.; Jorge Fernandez, M.; Pellon Augusto, M. L.; Paris Bouzas, L.; Garcia Gomez, J. published an article.Electric Literature of 65-71-4 The title of the article was Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram. And the article contained the following:
Introduction: Trifluridine/tipiracil combination has shown a benefit over placebo in the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC). We evaluated the efficacy and safety of this combination in the real-life setting at eight Galician centers in Spain. Patients and methods: This is a retrospective study of a cohort of patients with mCRC in treatment with trifluridine/tipiracil within usual clin. practice who have been previously treated or are not considered candidates for treatment with available therapies. Results: A total of 160 mCRC patients were included. Our data showed that 11.9% of patients achieved disease control. Median progression-free survival was 2.75 mo; at 5.66 mo follow-up, median overall survival was 7.94 mo. Asthenia and neutropenia (48.1% both) were the most frequent adverse events. Overall survival was lower in patients with ECOG 2, multiple metastatic sites, platelets count 350,000/μl, alk. phosphatase > 500 IU/l, and carcinoembryonic antigen > 10 ng/mL. Conclusion: The results of this study confirm the efficacy and safety of trifluridine/tipiracil in chemorefractory mCRC patients. However, patients in clin. practice differ from patients in clin. trials. Due to this, prognostic factors have special importance to offer the best therapeutic approach. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Electric Literature of 65-71-4
The Article related to metastatic colorectal cancer safety trifluridine tipiracil prognosis, metastatic colorectal cancer, nomogram, prognostic factors, real-life, refractory, trifluridine/tipiracil and other aspects.Electric Literature of 65-71-4
Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia